ReviewTheranostics2022
Therapeutic angiogenesis-based strategy for peripheral artery disease.
Review in Theranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- FGF-23 as a Biomarker for Carotid Plaque Vulnerability: A Systematic Review.Medical sciences (Basel, Switzerland) · 2025Pooled it
- Article
- SETD2 Improves Endothelial Function and Angiogenesis in Diabetic Hindlimb Ischemia Via Activating ANGPT2-PI3K/AKT Pathway.Cardiovascular toxicology · 2026Article
- Off‑the‑shelf, engineered non-living stem cell strategy for advancing cellular therapies.Nature biomedical engineering · 2026Article
- Prevascularized grafts with spatially organized MSC spheroids to accelerate therapeutic angiogenesis in ischemic disease.Angiogenesis · 2026Article
- Early Perioperative Changes in Circulating Hypoxia-Inducible Factor-1 Alpha (HIF-1A) and Vascular Endothelial Growth Factor (VEGF) Following Lower Limb Revascularisation for Peripheral Arterial Disease.Journal of clinical medicine · 2026Article
- HK2 promotes angiogenesis through H3K18 lactylation in peripheral arterial disease.Communications biology · 2026Article
- Small chemical molecule CPP promotes angiogenesis in surgically created severe lower limb ischemia and diabetes-induced limb vascular reduction models.Acta biochimica et biophysica Sinica · 2026Article
- VEGF as a predictor of major adverse events in patients with peripheral arterial disease - an exploratory study.Journal of thrombosis and thrombolysis · 2026Article
- hUCB-MSCs Secreted Exosomal miR-21-5p Promotes Vascular Endothelial Tip Cell Proliferation and Migration by Downregulating TGF-β1.Current stem cell research & therapy · 2026Article
- miR-765 induces angiogenesis by inhibiting dipeptidyl peptidase 4 and increasing fibroblast growth factor 2.BBA advances · 2026Article
- Profiling of main regulators of angiogenesis and inflammation in human PBMC and plasma revealed associations with lower extremity artery disease.Scientific reports · 2025Article
- A smooth muscle cell lncRNA controls angiogenesis in chronic limb-threatening ischemia through miR-143-3p/HHIP signaling.The Journal of clinical investigation · 2025Article
- Article
- MY-1 promotes angiogenesis in the ischemic hindlimbs by regulating the stability of CDC42 via PSMD14.Angiogenesis · 2025Article
- Endothelial metabolic zonation in the vascular network: a spatiotemporal blueprint for angiogenesis.American journal of physiology. Heart and circulatory physiology · 2025Review
- The Impact of Flavonoids and Omega-3 in Mitigating Frailty Syndrome to Improve Treatment Outcomes in Peripheral Artery Disease (PAD) Patients.Nutrients · 2025Review
- Delivery of Nucleic Acids for Vascular Tissue Engineering Applications.Regenerative engineering and translational medicine · 2025Article
- L-theanine promotes angiogenesis in limb ischemic mice by modulating NRP1/VEGFR2 signaling.Biomolecules & biomedicine · 2025Article
- Effect of platelet-rich plasma on angiogenic and regenerative properties in patients with critical limb ischemia.Regenerative therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral artery disease (PAD) poses a great challenge to society, with a growing prevalence in the upcoming years. Patients in the severe stages of PAD are prone to amputation and death, leading to poor quality of life and a great socioeconomic burden. Furthermore, PAD is one of the major complications of diabetic patients, who have higher risk to develop critical limb ischemia, the most severe manifestation of PAD, and thus have a poor prognosis. Hence, there is an urgent need to develop an effective therapeutic strategy to treat this disease. Therapeutic angiogenesis has raised concerns for more than two decades as a potential strategy for treating PAD, especially in patients without option for surgery-based therapies. Since the discovery of gene-based therapy for therapeutic angiogenesis, several approaches have been developed, including cell-, protein-, and small molecule drug-based therapeutic strategies, some of which have progressed into the clinical trial phase. Despite its promising potential, efforts are still needed to improve the efficacy of this strategy, reduce its cost, and promote its worldwide application. In this review, we highlight the current progress of therapeutic angiogenesis and the issues that need to be overcome prior to its clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.